Drug Approval | February 10, 2025
NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension
TFOS is indicated for the treatment of pulmonary arterial hypertension
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Plans underway to expand screening capacity by 50% for greater accessibility
Branded formulation business continues to perform well across domestic and export markets
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Cancer cases in India estimated to reach 1.57 million in 2025
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Subscribe To Our Newsletter & Stay Updated
